Chronic Disease Management

Understanding Multimorbidity and Polypharmacy: Foundations for Complex Care

Mrs. Ahmed, 72, arrives with her medication list: 14 regular tablets for type 2 diabetes, hypertension, heart failure, COPD, osteoarthritis, and depression. She's confused about timing, experiencing dizziness, and wondering if she really needs them all. This scenario exemplifies the twin challenges of multimorbidity (≥2 long-term conditions) and polypharmacy (≥5 regular medications) that now define modern primary care. Understanding these concepts is fundamental to safe, patient-centered chronic disease management, as approximately 27% of UK adults have multimorbidity, rising to 65% in those aged >65 years.

Core definitions with clinical thresholds:

• Multimorbidity : ≥2 chronic conditions co-existing (NICE NG56 definition)

  • Prevalence increases exponentially with age and socioeconomic deprivation
  • Associated with 7-fold increased mortality and doubled healthcare costs

• Polypharmacy : ≥5 regular medications (including OTC/supplements)

  • Appropriate polypharmacy: evidence-based, goal-concordant prescribing
  • Problematic polypharmacy: medications lacking indication or causing net harm
  • Risk of adverse drug reactions increases exponentially: 13% with 2 drugs → 58% with 5 drugs → 82% with ≥7 drugs

• Treatment burden: The workload of healthcare (appointments, monitoring, medication administration) and its impact on patient wellbeing

📌 Mnemonic for Polypharmacy Risks: "IMPACT" - Interactions, Medication errors, Poor adherence, Adverse reactions, Cognitive burden, Treatment burden

2 - Pathophysiology of Drug Interactions and Treatment Burden

The cascade from multimorbidity to problematic polypharmacy follows predictable pathways. Each additional condition typically triggers guideline-directed therapy, yet single-disease guidelines rarely account for comorbidities. A patient with heart failure, atrial fibrillation, and CKD stage 3 faces competing treatment priorities: beta-blockers for HF may worsen fatigue, warfarin requires INR monitoring adding treatment burden, and ACE inhibitors risk hyperkalemia with declining renal function. This creates a prescribing cascade where medication side effects are misinterpreted as new conditions requiring additional drugs.

Mechanisms driving problematic polypharmacy:

• Pharmacokinetic interactions : Altered absorption, distribution, metabolism, excretion

  • Cytochrome P450 enzyme induction/inhibition (e.g., clarithromycin increasing simvastatin levels 10-fold)
  • Competition for renal tubular secretion (NSAIDs reducing lithium clearance by 25-40%)

• Pharmacodynamic interactions: Additive/antagonistic effects at receptor/pathway level

  • Serotonin syndrome risk with SSRIs + tramadol (occurs in 14-16% combinations)
  • Orthostatic hypotension with α-blockers + antihypertensives (falls risk increased 2.4-fold)

• Age-related physiological changes amplifying drug effects:

  • Reduced renal clearance (GFR declines 1 mL/min/year after age 40)
  • Decreased hepatic first-pass metabolism
  • Altered volume of distribution (increased fat, decreased water)
  • Enhanced blood-brain barrier permeability to anticholinergics

3 - Conducting Structured Medication Reviews: The NICE Framework

Mr. Patel's GP notices his new prescription for prochlorperazine for "dizziness." Reviewing his records reveals he started amlodipine 10mg six weeks ago. Rather than adding another drug, a structured medication review identifies the prescribing cascade and reduces amlodipine to 5mg, resolving symptoms without additional medication. NICE NG5 recommends structured reviews for all patients with multimorbidity , particularly those on ≥10 medications or with problematic polypharmacy indicators.

NICE-recommended structured medication review process:

• Stage 1: Preparation (before consultation)

  • Compile complete medication list (including OTC, herbal, stopped medications)
  • Review recent blood tests, hospital letters, adherence data
  • Calculate renal function (eGFR), identify high-risk medications

• Stage 2: Medication review consultation

  • Assess indication: Does each drug have current evidence-based indication?
  • Evaluate effectiveness: Is therapeutic goal being achieved?
  • Check safety: Drug-drug interactions, contraindications, monitoring adherence
  • Explore patient perspective: Treatment burden, adherence barriers, goals

• Stage 3: Shared decision-making

  • Prioritize medications by patient-defined goals
  • Identify deprescribing opportunities (START/STOPP criteria)
  • Agree monitoring and follow-up plan

4 - Analyzing Prescribing Patterns: Identifying Inappropriate Polypharmacy

Distinguishing appropriate from problematic polypharmacy requires systematic analysis. The STOPP/START criteria (Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert to Right Treatment) identify potentially inappropriate medications and prescribing omissions in older adults. Version 2 includes 114 criteria across 13 organ systems, with evidence that application reduces adverse drug events by 21-36% and potentially inappropriate prescribing by 35-51%.

Key prescribing cascade patterns to recognize:

• Anticholinergic cascade: Antipsychotic for behavioral symptoms → urinary retention → α-blocker → orthostatic hypotension → falls

  • Use Anticholinergic Cognitive Burden scale: score ≥3 associated with 46% increased mortality

• Diuretic cascade: Loop diuretic → hypokalemia → potassium supplement → GI upset → PPI → C. difficile risk

• NSAID cascade : NSAID for arthritis → hypertension → additional antihypertensive → ankle edema → diuretic increase

🚩 Red Flag Prescribing Cascades: New medication started within 3 months of another without clear new diagnosis - always consider whether treating side effect rather than new condition.

5 - Deprescribing Decisions: Balancing Evidence and Patient Goals

Mrs. Chen, 85, with advanced dementia, continues simvastatin started 15 years ago for primary prevention. Her daughter asks: "Does mum still need this?" Deprescribing -the systematic process of tapering or stopping medications when harms outweigh benefits-requires evaluating time-to-benefit versus life expectancy, current goals of care, and medication-specific withdrawal risks. NICE NG56 emphasizes that for patients with multimorbidity , quality of life often outweighs strict guideline adherence.

Structured deprescribing approach:

• Identify deprescribing candidates :

  • Medications with time-to-benefit >1 year (statins, bisphosphonates) in limited life expectancy
  • Drugs causing adverse effects outweighing benefits
  • Medications no longer aligned with patient goals
  • Preventive medications in palliative phase

• Assess withdrawal risks:

  • High-risk withdrawals requiring tapering: Benzodiazepines (seizure risk), beta-blockers (rebound tachycardia), corticosteroids (adrenal crisis), PPIs (rebound hypersecretion)
  • Low-risk immediate stopping: Statins, bisphosphonates, most vitamins

• Implement with monitoring:

  • Stop one medication at a time (except when stopping prescribing cascade)
  • Review 1-4 weeks post-cessation
  • Document rationale and monitoring plan

⭐ Clinical Pearl: The best time to deprescribe is when adding a new medication-review the entire list and consider: "If I weren't already prescribing this, would I start it today?"

6 - Designing Individualized Care Plans for Complex Multimorbidity

Mr. Davies has heart failure (NYHA III), COPD (FEV1 35%), CKD stage 4 (eGFR 22), and depression. Applying individual disease guidelines would require 19 medications and 47 clinic appointments annually-an impossible treatment burden. NICE NG56 advocates individualized care planning that prioritizes patient-defined goals over guideline concordance, particularly when guidelines conflict or treatment burden becomes overwhelming.

Framework for complex multimorbidity management:

• Establish patient priorities through "What matters to you?" conversations

  • Functional goals (maintain independence, reduce breathlessness)
  • Quality vs. quantity of life preferences
  • Acceptable treatment burden threshold

• Identify dominant conditions and therapeutic synergies

  • Which condition most limits function/quality of life?
  • Which medications treat multiple conditions? (e.g., ACE inhibitor for HF + CKD + HTN)
  • Which treatments conflict? (beta-blockers for HF vs. COPD concerns-evidence shows safe in COPD)

• Rationalize monitoring and appointments:

  • Combine reviews where possible (annual diabetes + CKD review)
  • Reduce monitoring frequency for stable conditions
  • Use remote monitoring where appropriate

High Yield Summary

Key Take-Aways:

• Multimorbidity (≥2 conditions) affects 27% of UK adults, 65% of those >65 years; polypharmacy (≥5 medications) increases adverse drug reaction risk exponentially (82% with ≥7 drugs)
• Structured medication reviews using NICE NG5 framework should occur at least annually for patients with multimorbidity , focusing on indication, effectiveness, safety, and patient perspective
• Prescribing cascades-treating medication side effects as new conditions-are a key driver of problematic polypharmacy ; always consider recent medication changes when new symptoms emerge
• STOPP/START criteria reduce potentially inappropriate prescribing by 35-51% and adverse events by 21-36% in older adults
• Deprescribing decisions should balance time-to-benefit vs. life expectancy, withdrawal risks, and patient-centered goals over strict guideline adherence
• For complex multimorbidity, individualized care plans prioritizing patient-defined goals and reducing treatment burden improve outcomes over rigid guideline application

Essential Chronic Disease Management Numbers:

Key Principles:

• "Start low, go slow, but go"-titrate medications cautiously in multimorbidity, but don't withhold evidence-based therapy unnecessarily
• Always compile a complete medication list including OTC, herbal, and recently stopped medications before reviews
• One medication change at a time allows clear attribution of effects (except when stopping prescribing cascades)
• The question "If I weren't prescribing this already, would I start it today?" identifies deprescribing candidates
• Treatment burden is a clinical outcome-reducing pill burden and appointment frequency improves adherence and quality of life

Quick Reference: